Evidence map›Paper›PMID 38683900›Full record

ArticleCirculation2024

Empowering Valvular Heart Disease Research With Stem Cell-Derived Valve Cells.

Mengcheng Shen, Joseph C Wu

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Coordination of cardiogenesis in vivo and in vitro.Nature reviews. Molecular cell biology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Mengcheng ShenStanford Cardiovascular Institute (M.S., J.C.W.), Stanford University, CA.ORCID 0000-0001-7037-6159
Joseph C WuStanford Cardiovascular Institute (M.S., J.C.W.), Stanford University, CA.

Funding

Human iPSCs for Elucidating Intercellular Crosstalk Signaling in Dilated CardiomyopathyR01HL141371 · NHLBI · STANFORD UNIVERSITY · PI WONG, WING H., WU, JOSEPH C. · 2018 to 2025
$6.2M
Modeling Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction Using Human iPSCsR01HL141851 · NHLBI · STANFORD UNIVERSITY · PI WONG, WING H., WU, JOSEPH C. · 2018 to 2025
$5.7M
Modeling Susceptibility to Radiation Therapy-induced Cardiotoxicity Using Cell Village iPSCsR01HL171102 · NHLBI · STANFORD UNIVERSITY · PI MARK MERCOLA, Joseph C. Wu · 2024 to 2026
$2.1M
Elucidating anti-angiogenic tyrosine kinase inhibitor-induced vascular dysfunctionR00HL166693 · NHLBI · WASHINGTON UNIVERSITY · PI Mengcheng Shen · 2025 to 2026
$498k
Elucidating anti-angiogenic tyrosine kinase inhibitor-induced vascular dysfunctionK99HL166693 · NHLBI · STANFORD UNIVERSITY · PI SHEN, MENGCHENG · 2023 to 2024
$257k
NHLBI NIH HHS K99 HL166693NHLBI NIH HHS R00 HL166693NHLBI NIH HHS R01 HL141371NHLBI NIH HHS R01 HL141851NHLBI NIH HHS R01 HL171102
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Heart Valve DiseasesAnimalsHeart ValvesHumansStem CellsStem Cell TransplantationEditorialsendothelial cellsheart valve diseasesinduced pluripotent stem cells

Identifiers

PMID38683900
PMCPMC12034344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.